Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer

被引:2
|
作者
Ready, NE
Vokes, EE
机构
[1] Brown Univ, Sch Med, Providence, RI USA
[2] Univ Chicago, Dept Med Hematol, Oncol Sect, Chicago, IL USA
关键词
lung cancer; platinum; NSCLC;
D O I
10.1016/S0169-5002(03)00306-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chemoradiotherapy has been shown to improve survival over radiation alone for unresectable locally advanced non-small cell lung cancer (NSCLC). Large randomized trials comparing sequential to concomitant platinum based chemoradiotherapy have demonstrated improved median survival times in favor of concomitant treatment. Recent phase II trials have evaluated the integration of advanced radiotherapy techniques, novel chemotherapy combinations, induction chemotherapy, and consolidation chemotherapy with concomitant chemoradiotherapy. On-going or recently completed phase III trials are evaluating whether the promising regimens from phase II studies are superior to concomitant chemoradiotherapy alone. Molecular therapies now need to be integrated with chemoradiotherapy. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:S65 / S69
页数:5
相关论文
共 50 条
  • [41] A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer
    Sculier, Jean-Paul
    Lafitte, Jean-Jacques
    Berghmans, Thierry
    Meert, Anne-Pascale
    Scherpereel, Arnaud
    Roelandts, Martine
    Van Cutsem, Olivier
    Colinet, Benoit
    Bonduelle, Yves
    Giner, Vicente
    Paesmans, Marianne
    Leclercq, Nathalie
    Van Houtte, Paul
    [J]. LUNG CANCER, 2018, 117 : 32 - 37
  • [42] Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?
    Hong, Julian C.
    Salama, Joseph K.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 126 - 133
  • [43] Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
    Zhang, Xiaofei
    Zhang, Jianguo
    Liu, Peiyi
    Wang, Juan
    Zhao, Kuaile
    Zhu, Zhengfei
    Gu, Kangsheng
    Zhao, Weixin
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [44] Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer
    Vokes, EE
    [J]. LUNG CANCER, 2001, 33 : S85 - S89
  • [45] The therapy of locally advanced non-small cell lung cancer (NSCLC) in the elderly
    Schild, S. E.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 : S7 - S7
  • [46] Optimized local therapy for locally advanced non-small cell lung cancer
    Billiet, Charlotte
    De Ruysscher, Dirk
    [J]. JOURNAL OF THORACIC DISEASE, 2017, 9 (07) : 1783 - 1785
  • [47] Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?
    Berman, Abigail T.
    Simone, Charles B., II
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (01) : 138 - 142
  • [48] Multimodality treatment of advanced non-small cell lung cancer: Where are we with the evidence?
    Jones C.M.
    Brunelli A.
    Callister M.E.
    Franks K.N.
    [J]. Current Surgery Reports, 6 (2)
  • [49] Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer
    Kaya, Ali Osman
    Buyukberber, Suleyman
    Benekli, Mustafa
    Coskun, Ugur
    Sevinc, Alper
    Akmansu, Muge
    Yildiz, Ramazan
    Ozturk, Banu
    Yaman, Emel
    Kalender, Mehmet Emin
    Orhan, Okan
    Yamac, Deniz
    Uner, Aytug
    [J]. MEDICAL ONCOLOGY, 2010, 27 (01) : 152 - 157
  • [50] New drug and multimodality combinations in the treatment of advanced non-small cell lung cancer
    Kawahara, M
    Kris, MG
    Green, M
    Kunitoh, H
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (03) : 1 - 4